Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1
Daniel Coleman(University of Birmingham), Constanze Bonifer(Cancer Research UK Clinical Trials Unit)
Cited by 9
Related Papers
Subtype-specific regulatory network rewiring in acute myeloid leukemia
|Nature Genetics|2018|197
Identification of a Dynamic Core Transcriptional Network in t(8;21) AML that Regulates Differentiation Block and Self-Renewal
|Cell Reports|2014|123
Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth
|Nature Communications|2024|31
Developmental-stage-dependent transcriptional response to leukaemic oncogene expression
|Nature Communications|2015|27
Different mutant RUNX1 oncoproteins program alternate haematopoietic differentiation trajectories
|Life Science Alliance|2021|19